A good start today with Onalta. And next up is ...

From pre-clinical research to phase III candidates, this company is loaded with value. Brilliant strategy getting to this point, and clearly an exciting new phase is beginning.

On a side note, it's good to see that serious people are working hard to bring real value to the healthcare system, while reducing costs. Meanwhile, the clown-act in Washington continues.